Prostate cancer is the most frequent type of cancer in men.
It is estimated that 1 in 8 men will be diagnosed with prostate cancer during his lifetime.
CURRENT PROSTATE CANCER SCREENING IS CONTROVERSIAL
For the past 25 years, PSA-based (Prostate Specific Antigen) screening for prostate cancer has been widely implemented globally.
When levels of PSA are high, a biopsy of the prostate gland is usually indicated to make or discard the diagnosis of cancer.
This methodology often leads to unnecessary biopsies – a procedure that is expensive to the payers, disturbing for the patient and more invasive and dangerous than any other test.
PROSTATE CANCER DIAGNOSTIC PATHWAY
Levels of PSA higher than 3 (or 4 depending on the country’s protocol) may indicate prostate cancer.
When cancer is suspected, a prostate biopsy is performed. However, the majority of men with an elevated PSA do not actually have prostate cancer, but may have other reasons for an elevated PSA such as prostatitis or benign prostatic hyperplasia.
While annual PSA testing has reduced deaths from prostate cancer, urologists and health organizations over the world now recognize that it is possible to significantly improve the overall efficiency of screening.
ProsTAV is our new sophisticated prostate cancer risk score test that Life Length has developed with TAT technology thanks to a clinical study with over 1,200 prostate biopsied patients.
Combined with the current screening methodology, in patients with a PSA between 3 and 10, it can potentially save hundreds of thousands of men each year from unnecessary biopsies, surgeries, radiation treatments and needless complications.
The main purpose of our prostate cancer study was to determine if TAVs could contribute to better prostate cancer diagnosis. The results of this study were both based on internal and external analysis of a prospective cohort and fully validated.
ProsTAV only requires a simple blood draw and no fasting is required.